P08034 (MK3034-043): Efficacy & Safety study of Boc/PR in children wit

• Research type

  Research Study

• Full title

  A Phase 3 Study to Assess the Efficacy and Safety of Boceprevir in Combination with Peginterferon alfa-2b Plus Ribavirin in Paediatric Subjects With Chronic Hepatitis C Genotype 1

• IRAS ID

  105345

• Contact name

  Deirdre Kelly

• Contact email

  deirdre.kelly@bch.nhs.uk

• Sponsor organisation

  Merck Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc.

• Eudract number

  2010-024260-17

• Clinicaltrials.gov Identifier

  NCT01590225

• REC name

  London - Central Research Ethics Committee

• REC reference

  13/LO/0453

• Date of REC Opinion

  3 May 2013

• REC opinion

  Favourable Opinion